Claudia Sommer, MD, Professor of Neurology at the University of Würzburg, Germany, and Alex Seluzhytsky, MD, Senior Global Medical Director at Sanofi, discuss data on riliprubart for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP).
CIDP is a rare neurological disorder that causes progressive weakness and impaired sensory function, most notably in the legs and arms. Symptoms often include tingling or numbness (first in the toes and fingers), weakness of the arms and legs, loss of deep tendon reflexes, fatigue, and abnormal sensations. Other symptoms may include pain, dysphagia, and diplopia. CIDP is considered to be an autoimmune disease that targets the myelin sheath of the peripheral nerves.
Riliprubart is an investigational IgG4 humanized monoclonal antibody designed to selectively inhibit activated C1 protein in the classical complement pathway.
Data on riliprubart was recently presented at the 2025 Peripheral Nerve Society Annual Meeting from a phase 2 multicenter, open-label, non-randomized, proof-of-concept study evaluating the efficacy, safety, and tolerability of riliprubart in adults with CIDP. Patients were split into three cohorts: those on standard of care, those refractory to standard of care, and those who were treatment-naïve. All three groups showed significant improvement in disease following use of riliprubart.
Next steps include phase 3 trials where riliprubart will be compared to placebo. Two of these trials are ongoing and currently recruiting patients. For more information, click here.
To learn more about CIDP and other rare autoimmune conditions, visit https://checkrare.com/diseases/autoimmune-and-auto-inflammatory-disorders/